clinical trial · NCT05390710
PhI to Solid Tumors and PhII to Locally Advanced or mTNBC
Solid TumorTNBC - Triple-Negative Breast CancerLAE005 + Afuresertib + Nab-Paclitaxel
brief summary
PhI Dose Escalation with BOIN design in advanced Solid Tumor with Triple combination therapy to determine MTD and RP2D
started
Jun 12, 2021
primary completion
Dec 11, 2023
completion
Dec 11, 2023
last updated
Oct 10, 2024
detailed description
Phase I dose escalation for triple combination therapy with BOINcomb design,The safety (including DLT), tolerability, and PK are the study endpoints of phase I and to determine MTD and RP2D.
official title
A PhI Dose Escalation Study of LAE005+Afuresertib+Nab_Paclitaxel in Advanced Solid Tumors and PhII Study to Evaluate the Safety and Efficacy of LAE005+Afur+Nab_Paclitaxel or LAE005/Afur+Nab-Paclitaxel in Locally Advanced or mTNBC
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol